JP Morgan Maintains Overweight on Allogene Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng maintains an Overweight rating on Allogene Therapeutics (NASDAQ:ALLO) but lowers the price target from $9 to $8.

February 27, 2024 | 6:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Allogene Therapeutics but lowers the price target from $9 to $8.
The adjustment in price target by a major analyst like JP Morgan can influence investor sentiment. However, maintaining an Overweight rating suggests a positive outlook on the stock, potentially balancing the impact of the lowered price target. The direct mention and specific action taken by JP Morgan indicate a high relevance and importance to investors in ALLO. The confidence in this analysis is high due to the clear actions and ratings provided by a reputable financial institution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100